ScholarIQanswers from OpenAlex & ORCID
Claire J. Lansdall
ResearcherPublications, citations & collaboration network
Claire J. Lansdall is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Claire J. Lansdall have?
ScholarIQindexed works
Claire J. Lansdall has 24 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Claire J. Lansdall have?
ScholarIQcitation count
Claire J. Lansdall has 1,172 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Claire J. Lansdall?
ScholarIQh-index
Claire J. Lansdall has an h-index of 11 in OpenAlex.
What is the i10-index of Claire J. Lansdall?
ScholarIQi10-index
Claire J. Lansdall has an i10-index of 11 in OpenAlex.
What is the OpenAlex record for Claire J. Lansdall?
ScholarIQopenalex
The OpenAlex for Claire J. Lansdall is on the source record.
What are the most-cited papers on Claire J. Lansdall?
ScholarIQmost cited works
Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes
Ian Coyle‐Gilchrist, Katrina M. Dick, Karalyn Patterson, Patricia Vázquez Rodríquez, Eileen Wehmann, Alicia Wilcox, Claire J. Lansdall, Kate Dawson, Julie Wiggins, Simon Mead, Carol Brayne, James B. Rowe
Redefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes
Alexander G. Murley, Ian Coyle‐Gilchrist, Matthew A Rouse, P. Simon Jones, Win Li, Julie Wiggins, Claire J. Lansdall, Patricia Vázquez Rodríguez, Alicia Wilcox, Kamen A. Tsvetanov, Karalyn Patterson, Matthew A. Lambon Ralph, James B. Rowe
Apathy and impulsivity in frontotemporal lobar degeneration syndromes
Claire J. Lansdall, Ian Coyle‐Gilchrist, P. Simon Jones, Patricia Vázquez Rodríguez, Alicia Wilcox, Eileen Wehmann, Katrina M. Dick, Trevor W. Robbins, James B. Rowe
Prognostic importance of apathy in syndromes associated with frontotemporal lobar degeneration
Claire J. Lansdall, Ian Coyle‐Gilchrist, Patricia Vázquez Rodríguez, Alicia Wilcox, Eileen Wehmann, Trevor W. Robbins, James B. Rowe
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Sheila Seleri Assunção, Reisa A. Sperling, Craig Ritchie, Diana Kerwin, Paul Aisen, Claire J. Lansdall, Alireza Atri, Jeffrey L. Cummings